SCHEMBL2074192

SCHEMBL2074192

CNCCC(c1ccccc1)N1CCc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 12/20 0.57
SLC6A4 P31645 10/20 0.57
MAPT P10636 4/20 0.55
TP53 P04637 3/20 0.55
GAA P10253 2/20 0.55
GRM7 Q14831 1/20 0.48
LMNA P02545 1/20 0.47
HTR2A P28223 2/20 0.46
HRH1 P35367 2/20 0.46
CYP3A4 P08684 2/20 0.44
SLC22A2 O15244 1/20 0.44
SLC22A1 O15245 1/20 0.44
SLC22A3 O75751 1/20 0.44
CYP1A2 P05177 1/20 0.44
CHRM2 P08172 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20680476 0.85 SLC6A2 (0.46) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL28491789 0.81 MAPT (0.55) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL12963341 0.81 MAPT (0.55) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL1963702 0.81 MAPT (0.58) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL2074127 0.81 SLC6A2 (0.44) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL20680868 0.81 SLC6A2 (0.43) SLC6A2SLC6A4HTR2AHRH1
SCHEMBL20680475 0.81 L3MBTL1 (0.52) SLC6A2SLC6A4TP53LMNAHTR2A
SCHEMBL2073882 0.81 SLC6A2 (0.46) SLC6A2SLC6A4MAPTTP53GAA
SCHEMBL2074265 0.79 SLC6A2 (0.47) SLC6A2SLC6A4MAPTTP53LMNA
SCHEMBL2073396 0.79 SLC6A2 (0.47) SLC6A2SLC6A4TP53GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
US-7863305-B2 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC (US) 2011-01-04 US disclosed
EP-1756054-B1 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR HOFFMANN LA ROCHE (CH) 2010-03-31 EP disclosed
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors ROCHE PALO ALTO LLC 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025467-A1 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors TPH1, HTR1A, HTR3A SLC6A2 9/4885SLC6A4 14/4885MAPT 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.